Exelixis
EXEL
$21.12
Share price
0.62%
Change (1 day)
8.31%
Change (1 year)
Categories
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.
Exelixis (EXEL) - Total liabilities
Total liabilities on the balance sheet as of March 2024 : $0.67 B
According to Exelixis's latest financial reports the company's total liabilities are $0.67 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Exelixis - Total liabilities on balance sheet (from 2001 to 2024)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-12-31 | $0.67 B | 16.36% |
| 2022-12-31 | $0.58 B | 43.74% |
| 2021-12-31 | $0.40 B | 57.08% |
| 2020-12-31 | $0.25 B | 29.3% |
| 2019-12-31 | $0.19 B | 48.11% |
| 2018-12-31 | $0.13 B | -63.59% |
| 2017-12-31 | $0.37 B | -26.87% |
| 2016-12-31 | $0.50 B | 7.03% |
| 2015-12-31 | $0.47 B | 8% |
| 2014-12-31 | $0.43 B | 0.24% |
| 2013-12-31 | $0.43 B | 2.92% |
| 2012-12-31 | $0.42 B | 40.32% |
| 2011-12-31 | $0.30 B | -48.63% |
| 2010-12-31 | $0.58 B | 16.17% |
| 2009-12-31 | $0.50 B | 10.76% |
| 2008-12-31 | $0.45 B | 40.19% |
| 2007-12-31 | $0.32 B | 7.15% |
| 2006-12-31 | $0.30 B | 10.67% |
| 2005-12-31 | $0.27 B | 14.44% |
| 2004-12-31 | $0.24 B | 22.6% |
| 2003-12-31 | $0.19 B | 20.29% |
| 2002-12-31 | $0.16 B | 49.18% |
| 2001-12-31 | $0.10 B |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $101.94 B | 14,986.48% | 🇺🇸 USA |
 Pfizer PFE | $137.21 B | 20,205.47% | 🇺🇸 USA |
 Amgen AMGN | $90.92 B | 13,355.10% | 🇺🇸 USA |
 Sanofi SNY | $57.61 B | 8,425.86% | 🇫🇷 France |
 Merck MRK | $69.04 B | 10,116.89% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $82.48 B | 12,106.25% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $57.22 B | 8,368.31% | 🇬🇧 UK |
 Curis CRIS | $57.61 M | -91.47% | 🇺🇸 USA |
 AVEO Oncology
AVEO | $72.38 M | -89.29% | 🇺🇸 USA |